The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.
Clinical trial NCT05317767 · COMPLETED
Trial details
- NCT number
- NCT05317767
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-02-10
- Primary completion
- 2020-07-05
- Enrollment
- 600
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.